Compare TASK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TASK | ANL |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 611.1M |
| IPO Year | 2021 | 2022 |
| Metric | TASK | ANL |
|---|---|---|
| Price | $5.08 | $9.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $14.70 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 617.9K | 144.9K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.95 | $36.02 |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $19.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $0.88 |
| 52 Week High | $18.39 | $17.25 |
| Indicator | TASK | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 40.75 |
| Support Level | $4.47 | $9.46 |
| Resistance Level | $6.62 | $9.98 |
| Average True Range (ATR) | 0.30 | 1.35 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 46.32 | 27.46 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.